Your session is about to expire
← Back to Search
Personalized Therapy for Acute Myeloid Leukemia
Study Summary
This trial will study the impact of clinicogenetic risk-stratified management on outcomes of acute myeloid leukemia in older patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have recent serious heart issues that would stop me from starting chemotherapy.I have serious kidney or liver problems that could make chemotherapy unsafe for me.I can care for myself but may need occasional help.I was treated with ATRA or ATO for a misdiagnosed APL.My AML cancer has returned or didn't respond to treatment and needs more therapy.I do not have any serious infections that are not under control.I am 60 years old or older.I need urgent chemotherapy for my leukemia due to severe complications.I have been newly diagnosed with a type of acute myeloid leukemia or a related condition.I have previously been treated with decitabine or azacitidine.My heart's pumping ability is below 45%.I have been diagnosed with acute promyelocytic leukemia.
- Group 1: Group I
- Group 2: Group II
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what medical contexts is Cytarabine most often employed?
"Cytarabine is an accepted treatment option for meningeal leukemia, induction chemotherapy, and acute myelocytic leukemia."
Are there any openings remaining in this clinical trial?
"This clinical trial is no longer open for enrollment; it was initiated on July 7th 2017 and closed to new patients on November 4th 2022. Currently, 1472 trials are actively looking for participants with leukemia or myeloid conditions, while 630 studies are recruiting individuals that may benefit from Cytarabine treatment."
What is the aggregate amount of people who are engaging in this research study?
"At this moment, no new candidates are being sought after for the research in question. It was first posted on July 7th 2017 and last edited November 4th 2022. For those looking to join a medical trial, 1472 clinical trials actively recruiting patients with leukemia or myeloid diseases exist, as well as 630 studies involving Cytarabine."
What is the current regulatory status of Cytarabine?
"The safety of Cytarabine has been given a rating of 2 by Power, as it is currently in the second phase of clinical trials without any proof for efficacy."
Could you enlighten me on prior studies involving Cytarabine?
"Presently, 630 Cytarabine studies are being conducted with 122 in the late stages. The majority of these trials take place in Toronto, Ontario but there is also a significant presence at 22558 other sites worldwide."
Share this study with friends
Copy Link
Messenger